ストックスクリーナーアプリを入手
0.779
0.52%
0.004
アフターアワーズ：
.80
0.021
+2.70%
前日終値:
$0.775
開ける：
$0.78
24時間の取引高:
142.96K
Relative Volume:
0.18
時価総額：
$8.81M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-9.42%
1か月 パフォーマンス:
+1.86%
6か月 パフォーマンス:
-92.97%
1年 パフォーマンス:
-99.59%
1日の値動き範囲:
$0.76
$0.7999
1週間の範囲:
$0.76
$0.8723
52週間の値動き範囲:
$0.375
$215.31
AEON Biopharma Inc. Stock (AEON) Company Profile
AEON を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AEON
AEON Biopharma Inc.
|
0.779 | 9.72M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
AEON Biopharma Inc. Stock (AEON) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-08-18 | 開始されました | H.C. Wainwright | Buy |
AEON Biopharma Inc. (AEON) 最新ニュース
why aeon biopharma inc. stock attracts strong analyst attentionSmart Growth Low Risk Picks - Newser
what makes aeon biopharma inc. stock price move sharplyROI Focused Stock Calls - Newser
Why AEON Biopharma Inc. stock attracts strong analyst attentionFree Professional Portfolio Management - Newser
What makes AEON Biopharma Inc. stock price move sharplyFree Access to Investment Community - Newser
How AEON Biopharma Inc. stock performs during market volatilitySmart Return Focused Trading - Newser
AEON Biopharma (NASDAQ:AEON) Trading Down 10.2% – Should You Sell? - Defense World
AEON Biopharma Holds Annual Stockholders Meeting - TipRanks
AEON Biopharma, Inc. (NASDAQ:AEON) Short Interest Update - Defense World
AEON Biopharma Soars 13.67% on CEO Appointment, Talent Grants - AInvest
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 - The Manila Times
Aeon Biopharma Reports Positive Q1 2025 Earnings - TipRanks
AEON Biopharma Releases New Corporate Presentation - TipRanks
AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025 - The Manila Times
AEON Biopharma to Present Corporate Overview at Aegis Capital Corp. 2025 Virtual Conference - Nasdaq
AEON Biopharma Unveils Next-Gen Botulinum Toxin Therapies: CEO Details Multi-Indication Pipeline - Stock Titan
AEON Biopharma Advances Biosimilar Product Development and Appoints New CEO - Nasdaq
AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
New AEON CEO Targets $3.3B Botox Market with FDA-Ready Biosimilar Development Plan - Stock Titan
AEON Biopharma (AEON) Projected to Post Quarterly Earnings on Tuesday - Defense World
Closing Bell Recap: AEON Biopharma Inc (AEON) Ends at 0.75, Reflecting a -11.76 Downturn - DWinneX
AEON Biopharma Inc (AMEX: AEON) Stock: Investors Need To Know This - Stocksregister
Is AEON Biopharma Inc’s (AMEX:AEON) Stock On The Decline? - Stocksregister
AEON Biopharma gets NYSE American nod for compliance plan - Investing.com Australia
AEON Biopharma gets NYSE American nod for compliance plan By Investing.com - Investing.com Canada
AEON Biopharma Says NYSE American Accepts Plan to Regain Compliance - marketscreener.com
AEON Biopharma Receives Acceptance from NYSE American to Regain Compliance with Listing Standards - Nasdaq
AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance - The Manila Times
NYSE American Grants AEON Biopharma 2-Year Lifeline to Meet Listing Requirements - Stock Titan
AEON Biopharma’s Fight to Stay Listed: A High-Stakes Gamble? - AInvest
What was AEON Biopharma Inc (AEON)’s performance in the last session? - uspostnews.com
Analyzing the Impact of Earnings Reports on AEON Biopharma Inc Inc. (AEON) Price Performance - investchronicle.com
Who’s Hired? Botox Biosimilar Developer Aeon Takes CEO From Rival Revance - insights.citeline.com
AEON Biopharma, Inc. Announces Executive Changes, Effective as of April 4, 2025 - marketscreener.com
AEON Biopharma announces CEO appointment - MSN
AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer - The Manila Times
AEON Biopharma names Rob Bancroft as new CEO By Investing.com - Investing.com South Africa
Aeon Biopharma Names Robert Bancroft CEO - marketscreener.com
AEON Biopharma Appoints New CEO Robert Bancroft - TipRanks
Aeon Biopharma (AEON) Appoints Rob Bancroft as New CEO | AEON Stock News - GuruFocus
AEON Biopharma Appoints Rob Bancroft as CEO - MarketWatch
AEON Biopharma names Rob Bancroft as new CEO - Investing.com
AEON Biopharma (NASDAQ:AEON) Trading 2.5% Higher – Time to Buy? - Defense World
AEON Biopharma announces new interim CEO and CFO By Investing.com - Investing.com Australia
AEON Biopharma Inc. (AEON) 財務データ
AEON Biopharma Inc. (AEON) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.64%
0.37%
大文字化:
|
ボリューム (24 時間):